UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Effect of Garlic Supplements on the Pharmacokinetics of Saquinavir

Clinical infectious diseases, 2002-01, Vol.34 (2), p.234-238

2002

Volltextzugriff (PDF)

Modulation of human corticomotor excitability by somatosensory input

The Journal of physiology, 2002-04, Vol.540 (2), p.623-633

2002

Volltextzugriff (PDF)

A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Varenicline for Smoking Cessation

Clinical pharmacokinetics, 2010-12, Vol.49 (12), p.799-816

2010

Volltextzugriff (PDF)

O4‐11‐04: LINKING DIABETES AND ALZHEIMER'S DISEASE THROUGH RAGE: A RETROSPECTIVE ANALYSIS OF AZELIRAGON PHASE 2 AND PHASE 3 STUDIES

Alzheimer's & dementia, 2019-07, Vol.15 (7S_Part_24)

2019

Volltextzugriff (PDF)

Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy

Alzheimer's & dementia : translational research & clinical interventions, 2017-09, Vol.3 (3), p.339-347

2017

Volltextzugriff (PDF)

Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations

Annals of neurology, 2001-06, Vol.49 (6), p.706-711

2001

Volltextzugriff (PDF)

Multiple-Dose Pharmacokinetics of the Selective Nicotinic Receptor Partial Agonist, Varenicline, in Healthy Smokers

Journal of clinical pharmacology, 2006-12, Vol.46 (12), p.1439-1448

2006

Volltextzugriff (PDF)

Effect of TTP488 in patients with mild to moderate Alzheimer's disease

BMC neurology, 2014-01, Vol.14 (1), p.12-12, Article 12

2014

Volltextzugriff (PDF)

Indinavir concentrations and St John's wort

The Lancet (British edition), 2000-02, Vol.355 (9203), p.547-548

2000

Volltextzugriff (PDF)

Assessment of Azeliragon QTc Liability Through Integrated, Model‐Based Concentration QTc Analysis

Clinical pharmacology in drug development, 2019-05, Vol.8 (4), p.426-435

2019

Volltextzugriff (PDF)

AZELIRAGON PHASE 2B SURVIVAL ANALYSIS SUPPORTS BENEFICIAL EFFECTS ON DELAYING TIME TO COGNITIVE DETERIORATION IN PATIENTS WITH MILD ALZHEIMER'S DISEASE

Alzheimer's & dementia, 2016-07, Vol.12 (7), p.P352-P352

2016

Volltextzugriff (PDF)

Safety and Pharmacology of Ponezumab (PF-04360365) After a Single 10-Minute Intravenous Infusion in Subjects With Mild to Moderate Alzheimer Disease

Clinical neuropharmacology, 2013, Vol.36 (1), p.8-13

2013

Volltextzugriff (PDF)

Single-Dose Pharmacokinetics of Varenicline, a Selective Nicotinic Receptor Partial Agonist, in Healthy Smokers and Nonsmokers

Journal of clinical pharmacology, 2006-09, Vol.46 (9), p.991-998

2006

Volltextzugriff (PDF)

Pharmacokinetics, Safety, and Tolerability Following Multiple Oral Doses of Varenicline Under Various Titration Schedules in Elderly Nonsmokers

Journal of clinical pharmacology, 2011-04, Vol.51 (4), p.492-501

2011

Volltextzugriff (PDF)

Effect of Milk Thistle on the Pharmacokinetics of Indinavir in Healthy Volunteers

Pharmacotherapy, 2002-05, Vol.22 (5), p.551-556

2002

Volltextzugriff (PDF)

Pharmacokinetics, Safety, and Tolerability After Single and Multiple Oral Doses of Varenicline in Elderly Smokers

Journal of clinical pharmacology, 2006-11, Vol.46 (11), p.1234-1240

2006

Volltextzugriff (PDF)

Plasma Pharmacokinetics of Sulfadiazine Administered Twice Daily versus Four Times Daily Are Similar in Human Immunodeficiency Virus-Infected Patients

Antimicrobial Agents and Chemotherapy, 2004-02, Vol.48 (2), p.635-637

2004

Volltextzugriff (PDF)

Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers

Clinical pharmacology and therapeutics, 2000-12, Vol.68 (6), p.605-612

2000

Volltextzugriff (PDF)

Cytochrome P450 3A4 activity after surgical stress

Critical care medicine, 2003-05, Vol.31 (5), p.1338-1346

2003

Volltextzugriff (PDF)

Increase in tiagabine serum concentration with coadministration of gemfibrozil

The Annals of pharmacotherapy, 2009-02, Vol.43 (2), p.379-382

2009

Volltextzugriff (PDF)

LINKING DIABETES AND ALZHEIMER’S DISEASE THROUGH RAGE: A RETROSPECTIVE ANALYSIS OF AZELIRAGON PHASE 2 AND PHASE 3 STUDIES

Alzheimer's & dementia, 2019-07, Vol.15 (7), p.P1263-P1263

2019

Volltextzugriff (PDF)

O4‐11‐04: LINKING DIABETES AND ALZHEIMER'S DISEASE THROUGH RAGE: A RETROSPECTIVE ANALYSIS OF AZELIRAGON PHASE 2 AND PHASE 3 STUDIES

Alzheimer's & dementia, 2019-07, Vol.15, p.P1263-P1263

2019

Volltextzugriff (PDF)

Effects of azeliragon on ADAS‐cog and CDR domains and individual items in patients with mild Alzheimer's disease and type 2 diabetes (T2D)

Alzheimer's & dementia, 2020-12, Vol.16, p.n/a

2020

Volltextzugriff (PDF)

Effects of azeliragon on ADAS‐cog and CDR domains and individual items in patients with mild Alzheimer's disease and type 2 diabetes (T2D): Human/Human trials: Other

Alzheimer's & dementia, 2020-12, Vol.16 (S9)

2020

Volltextzugriff (PDF)

Metabolism and disposition of a gamma-aminobutyric acid type A receptor partial agonist in humans

Drug metabolism and disposition, 2008-04, Vol.36 (4), p.655-662

2008

Volltextzugriff (PDF)

1 – 25 von 69

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(66)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(67)
Bücher
(1)
Reviews
(1)

Sprache

Englisch
(68)

Erscheinungsjahr

n.n

Thema

Science & Technology
(42)
Humans
(40)
Life Sciences & Biomedicine
(40)
Male
(31)
Female
(29)
Pharmacology & Pharmacy
(27)
Biological And Medical Sciences
(25)
Medical Sciences
(25)
Pharmacology. Drug Treatments
(22)
Adult
(21)
Middle Aged
(19)
Adolescent
(10)
Aged
(9)
Neurology
(9)
Pharmacokinetics
(9)
Administration, Oral
(8)
Double-Blind Method
(8)
Neuropharmacology
(8)
Drug Interactions
(7)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Effect of Garlic Supplements on the Pharmacokinetics of Saquinavir

Modulation of human corticomotor excitability by somatosensory input

A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Varenicline for Smoking Cessation

O4‐11‐04: LINKING DIABETES AND ALZHEIMER'S DISEASE THROUGH RAGE: A RETROSPECTIVE ANALYSIS OF AZELIRAGON PHASE 2 AND PHASE 3 STUDIES

Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy

Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations

Multiple-Dose Pharmacokinetics of the Selective Nicotinic Receptor Partial Agonist, Varenicline, in Healthy Smokers

Effect of TTP488 in patients with mild to moderate Alzheimer's disease

Indinavir concentrations and St John's wort

Assessment of Azeliragon QTc Liability Through Integrated, Model‐Based Concentration QTc Analysis

AZELIRAGON PHASE 2B SURVIVAL ANALYSIS SUPPORTS BENEFICIAL EFFECTS ON DELAYING TIME TO COGNITIVE DETERIORATION IN PATIENTS WITH MILD ALZHEIMER'S DISEASE

Safety and Pharmacology of Ponezumab (PF-04360365) After a Single 10-Minute Intravenous Infusion in Subjects With Mild to Moderate Alzheimer Disease

Single-Dose Pharmacokinetics of Varenicline, a Selective Nicotinic Receptor Partial Agonist, in Healthy Smokers and Nonsmokers

Pharmacokinetics, Safety, and Tolerability Following Multiple Oral Doses of Varenicline Under Various Titration Schedules in Elderly Nonsmokers

Effect of Milk Thistle on the Pharmacokinetics of Indinavir in Healthy Volunteers

Pharmacokinetics, Safety, and Tolerability After Single and Multiple Oral Doses of Varenicline in Elderly Smokers

Plasma Pharmacokinetics of Sulfadiazine Administered Twice Daily versus Four Times Daily Are Similar in Human Immunodeficiency Virus-Infected Patients

Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers

Cytochrome P450 3A4 activity after surgical stress

Increase in tiagabine serum concentration with coadministration of gemfibrozil

LINKING DIABETES AND ALZHEIMER’S DISEASE THROUGH RAGE: A RETROSPECTIVE ANALYSIS OF AZELIRAGON PHASE 2 AND PHASE 3 STUDIES

O4‐11‐04: LINKING DIABETES AND ALZHEIMER'S DISEASE THROUGH RAGE: A RETROSPECTIVE ANALYSIS OF AZELIRAGON PHASE 2 AND PHASE 3 STUDIES

Effects of azeliragon on ADAS‐cog and CDR domains and individual items in patients with mild Alzheimer's disease and type 2 diabetes (T2D)

Effects of azeliragon on ADAS‐cog and CDR domains and individual items in patients with mild Alzheimer's disease and type 2 diabetes (T2D): Human/Human trials: Other

Metabolism and disposition of a gamma-aminobutyric acid type A receptor partial agonist in humans

Suchergebnisse filtern